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Univers
osting by E
cense.Abstract The current study is a hospital based investigation, in which attempts were being made to
establish the effect of falciparum malarial infection on cholesterol level and platelet counts. The
level of parasitaemia and its correlation with cholesterol level and platelet count in malaria patients
was investigated. Two hundred clinically diagnosed malaria patients and 200 age matched healthy
blood donors were included in the current study. In each case, blood sample was analyzed for serum
cholesterol level and platelet count to establish a correlation between such parameters with parae-
sitemia. Based on the results obtained, it was evident that there was a highly signiﬁcant reduction in
the serum cholesterol level and the platelet count in malaria patients having high levels of parasita-
emia. The low levels of cholesterol and platelets in malaria patients provided basis for the possible
use of such clinical data in the diagnosis of malaria in the absence of a positive blood ﬁlm.
ª 2009 King Saud University. Open access under CC BY-NC-ND license.1. Introduction
Malaria is a parasitic disease that occurs in tropical and sub-
tropical regions of the world. About 500 million cases of ma-
laria occur every year, and one million people, mostly
children living in sub-Saharan Africa, die as a result. The ma-
laria parasite Plasmodium falciparum was found to establish a(I.A. Al-Omar).
ity.
lseviersuccessful infection in the human host by interacting with a
variety of human proteins on the surface of different cells
types, as well as with proteins inside the host cells (Vignali
et al., 2008; Tuterja, 2007). The World Health Organization
has revived its earlier programs on malaria eradication, which
lead to a non-signiﬁcant outcome (Tuterja, 2007; WHO, 2006;
WHO/PAHO, 2006; WHO/Regional Ofﬁce for Europe, 2006;
WHO/Regional Ofﬁce for the Eastern Mediterranean, 2007).
The parasite mainly responsible for these deaths is P. falcipa-
rum which is transmitted to people through the bites of in-
fected mosquitoes (Barat, 2006). The release of information
on malaria in the public domain was voiced again in order
to help focus future resources for P. falciparummalaria control
and elimination (Barat, 2006; Guerra et al., 2008). New meth-
ods for the detection of malaria were part of the recommenda-
tions (Guerra et al., 2008). To provide efﬁcient allocation of
resources to intervene against malaria, several steps were
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2006). In some areas decline of malaria morbidity and mortal-
ity was reported due to applying effective combination of con-
trol methods (Nyarango et al., 2006; Meleigy, 2007).
Malaria is prevalent in many Muslim countries and the
frequency of falciparum specie seems to increase as compared
to vivax malaria (Zaher et al., 2007). In Saudi Arabia differ-
ent studies showed the presence of imported malaria as well
as some regions were known for malaria. During Hajj season,
many pilgrims were diagnosed to be suffering from falcipa-
rum malaria (Khan et al., 2002). The majority of the malaria
patients develop haematological complications and altera-
tions in biochemical parameters (Khan et al., 2002). The
changes in lipid composition and cholesterol exchange could
have a marked effect on the function of the red cell mem-
brane of malaria-infected cells and may be responsible, in
part, for the increased ﬂuidity and permeability of P. falcipa-
rum-infected erythrocytes (Maquire and Sherman, 1990).
Platelet kinetics and value of hypocholesterolaemia in travel-
lers returning from endemic areas were also worked out
(Karanikas et al., 2004; Badiaga et al., 2002). However, a
controversy immerged when in an earlier study no change
in the plasma cholesterol during and after infection was re-
ported (Onongbu and Onyeneke, 1983). Later it was pointed
out that parasites may metabolize cholesterol in severe infec-
tion and with some enzymes allows the parasite to break up
the cell and consume lipids and cholesterol (Bansal et al.,
2005).
Cholesterol in the body either originates from the diet or is
synthesised by the body and despite its beneﬁcial effects, cho-
lesterol concentration is positively associated with coronary
heart disease (Rader et al., 1994; Naito, 2003). The causes of
primary hypercholesterolaemia were associated with over pro-
duction of very low density lipoprotein (VLDL), increased
conversion of VLDL to low density lipoprotein (LDL), LDL
enriched with cholesteryl esters, defective LDA structure,
and decreased LDL receptor number or activity on each cell.
However, secondary hypercholesterolaemia was associated
with hypothyroidism, and obstructive liver disease, and obes-
ity, physical inactivity and fat rich diet (Rader et al., 1994).
Changes in blood cells and platelets in falciparum malaria
and their correlation with disease outcome were highlighted
(Guerra et al., 2008; Zaher et al., 2007; Karanikas et al.,
2004). In current study, the effects of malaria on platelets
and cholesterol were investigated to ensure their possible role
in diagnosis of malaria and the results are presented in this
communication.Table 1 The demographic data for the patients and control
groups.
Gender Patients Control Percent
Male 151 151 75.5
Female 49 49 24.52. Materials and methods
2.1. Patients and healthy controls
Two hundred malaria patients who presented clinically with
signs and symptoms of malaria infection, diagnosed in the ma-
laria clinic, were prospectively examined during the ﬁrst 12-
month period of the current study. All the malaria patients
were selected from Gizan region located in south-west part
of Saudi Arabia. As a control, 200 healthy blood donors,
matched in age and sex to the patient group, belonging to
non-endemic areas were examined in parallel using the same
investigative techniques.2.2. Blood sampling procedures
Venous blood samples (7 mL) were collected in Vacutainer
tubes from the antecubital vein using sterile venipuncture pro-
cedures; 5 mL of the sampled blood was collected in EDTA
anticoagulant tubes (K3 EDTA) and tested immediately, while
the remaining 2 mL of the sample was collected in a plain tube
and allowed to clot in a water bath at 37 C. Following clot
retraction and separation, aliquots of serum were stored in
plain plastic tubes at 20 C until processed.
2.3. Measurement of platelet count
The platelet count was measured for patients and controls by
automated depolarization of laser light (Cell-Dyn 3200,
Abbott, Santa Clara, CA) Haematology Cell count/Analyzer.
2.4. Measurement of cholesterol level
The cholesterol level was measured in all the 400 subjects in the
patients’ group and control group using Dimension automatic
clinical chemistry analyzer machine (Dade Behring, USA).
Principle of procedure: cholesterol esterase (CE) catalyzes
the hydrolysis of cholesterol esters to produce free cholesterol
which, along with pre-existing free cholesterol, is oxidised, in a
reaction catalyzed by cholesterol oxidase (CO), to form cho-
lest-4-ene-3-one and hydrogen peroxide. In the presence of
horseradish peroxidase (HRPO), hydrogen peroxide that is
formed is used to oxidise N,N-diethylaniline-HCl/4-aminoanti-
pyrine (DEA-HCl/AAP) to produce a chromophore which is
absorbed at 540 nm. The absorbance due to oxidised DEA-
HCl/AAP is directly proportional to the total cholesterol con-
centration and is measured using a polychromatic (540, 452
and 700 nm) endpoint technique.
2.5. Statistical analysis
The clinical and laboratory data was presented in an investiga-
tive report form. These data were transferred to an IBM per-
sonal computer running the statistical program SPSS-V-9
under Windows, to obtain the following descriptive statistics:
mean, standard deviation (SD), standard error of the mean
(SE) and range.
3. Results
The results obtained during the current study are summarized
in Tables 1–5, and Figs. 1 and 2.
The majority of patients in the study group (75.5%) were
male.
The study covered patients with a wide range of ages (12–
88 years); their mean age ± SD was 39.81 ± 16.09 years.
Their mean platelet count was 95.24 · 109/L ± 69.55 and their
Table 2 Quantitative data on age, platelets, and cholesterol
levels in patients.
Parameters Mean Standard
deviation
(±SD)
Standard
error
(±SE)
Range
Age 39.81 16.09 1.14 12–88
Platelet (150 · 109/L) 95.24 64.55 4.56 22–468
Cholesterol (1.93 ±
1.59 mmol/L)
1.93 1.59 0.11 0.2–6.3
Table 3 Quantitative data showing platelet count and cho-
lesterol levels of control.
Parameters Mean Standard
deviation
(±SD)
Standard
error
(±SE)
Range
Platelet (150 · 109/L) 221.96 69.39 4.91 130–400
Cholesterol (1.93 ±
1.59 mmol/L)
3.60 0.99 0.069 1.4–5.2
Effect of falciparum malaria infection on blood cholesterol and platelets 85mean cholesterol level was 1.93 mmol/L ± 1.59. All patients
had P. falciparum infection. Other species were looked for by
using thick blood ﬁlm and none was found.
The mean platelet count for the control group was
221.96 · 109/L ± 69.39 and it ranged between 130 · 109/L
and 400 · 109/L; the mean cholesterol level was 3.6 mmol/
L ± 0.99, ranging between 1.4 mmol/L and 5.2 mmol/L.
The Table 5 demonstrates that the mean value of the cho-
lesterol level was lower (1.93 ± 1.59) in the patient group than
the control group (3.60 ± 0.99). Similarly, it was evident that
the platelet count was lower (95.24 ± 64.55) in the patient
group as compared to the control group (221.96 ± 69.39).
The Mann–Whitney test revealed that these differences be-
tween the patients and the control groups were statistically sig-
niﬁcant (p< 0.001).
The data presented in Table 5 clearly demonstrated a signif-
icant inverse correlation between the parasite counts on oneTable 4 Showing the comparison between serum cholesterol level a
controls.
Cholesterol vs.
platelet count
SE of platelets
distribution
Mean plasma
platelets ± SD
Range
platelet
Normal group 4.91 221.96 ± 69.39 130–40
Patient group 4.56 95.24 ± 64.55* 22–468
* p< 0.001 (Mann–Whitney test).
Table 5 Showing the regression model for parasite count versus seru
group.
Variables Coeﬃcient SE
Constant 27625.39 1743.449
Serum cholesterol level 3092.6 694.284
Platelet count 104.797 15.405
Dependent variable: parasite count.hand and both the platelet count and cholesterol level on the
other. The results are depicted in Figs. 1 and 2.
The regression model illustrated above indicates the follow-
ing equation for relating the cholesterol level and platelet
count to the parasite count for each malaria patient:
Parasite count ¼ 27625:39 3092:6 serum cholesterol level
 104:797 platelet count:
Taking the standard error into consideration, the correla-
tion between platelet count and cholesterol level was highly
signiﬁcant (p<0.001) in the malaria patient group, but non-
signiﬁcant in the control group. The inverse correlation be-
tween platelet count and parasite counts/lL is given in Fig. 1
(Pearson correlation = 0.539). Fig. 1 is a scatter plot matrix
showing the trend line for the correlation between the parasite
count and platelet count for the patient group. There was a
signiﬁcant and consistent decrease in the platelet count with
increased parasite count (Pearson correlation = 0.539,
p< 0.001).
Again, there was a clear and signiﬁcant inverse correlation
between parasite count and cholesterol level among the pa-
tients (Pearson correlation = 0.452; Fig. 2).
4. Discussion
The results of the current study clearly showed reduction in
platelets between malaria patient group and the control group,
and it was statistically highly signiﬁcant (p< 0.001). In the
control group such changes were non-signiﬁcant. There was
a signiﬁcant inverse correlation between parasite count and
platelet count in the patient group. Our ﬁndings corroborated
well with the earlier reports, where a similar decrease in mean
platelet count of malaria patients (89.7 · 109/L) was noticed
which was signiﬁcantly lower as compared to the control
(Scott et al., 2003). It is worth mentioning that 89% of malaria
patients were found to be thrombocytopenic while 30% of the
patients were suffering from severe thrombocytopenia
(<50 · 109/L). Our ﬁnding are in agreement with anothernd platelet count in the malaria positive patients and the normal
of
s
SE of cholesterol
distribution
Mean serum
cholesterol ±
SD in mg/L
Range of
cholesterol
level in mg/L
0 0.069 3.60 ± 0.99 1.4–5.2
0.110 1.93 ± 1.59* 0.2–6.3
m cholesterol level and plasma platelet count among the patient
Standardised coeﬃcient t p
– 15.845 <0.001
0.279 4.454 <0.001
0.426 6.803 <0.001
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Figure 1 Figure showing inverse correlation between platelet
count and parasite counts/lL (Pearson correlation = 0.539).
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Figure 2 Correlation between parasite count and cholesterol
level among patients. There was a signiﬁcant inverse correlation
between parasite count and serum cholesterol level (Pearson
correlation = 0.452).
86 I.A. Al-Omar et al.study conducted in travellers coming from endemic areas
(D’Acremont et al., 2002), and 82% of them were found to
have fever. All of them were diagnosed to be suffering from
malaria. The platelet count in those cases was low, however,
10% cases had very low platelet count (<50 · 109/L). Further
studies on imported malaria patients revealed 77% and in an-
other case 95% patient were having thrombocytopenia (Han-
schoid et al., 2003; Badiaga et al., 2003). Song et al. (2003)
also found thrombocytopenia as a prominent feature in 75%
malaria patients. Our current results added support to earlier
studies, thus conﬁrming that thrombocytopenia was the most
sensitive abnormality in malaria patients.
Patel et al. (2004) observed the sensitivity of platelets count
to be 100% whereas the speciﬁcity was 70%. However, the
negative and positive predictive values were 100% and 86%,
respectively (Patel et al., 2004). Other workers reported the
sensitivity of thrombocytopenia (<150 · 109/L) to be 60%
and the speciﬁcity 88%. The haematological parameters
mostly could discriminate malaria from non-malarious acutefebrile illness (Lathia and Joshi, 2004). Febrile persons with
platelet counts <150 · 109/L, were 12–15 times more likely
to have malaria as compared to the control (Earhart et al.,
2004). In children with malaria, platelet counts of: <150 ·
109/L was found in 56.7% (Ladhami et al., 2002). Earlier, in
about 67% of imported malaria patients, thrombocytopenia
was <150 · 109/L, while in 33% of them it reached to
<100 · 109/L (Richards et al., 1998). Another report sug-
gested thrombocytopenia <150 · 109/L in 80% of malaria pa-
tients; and the platelet count of <50 · 109/L was seen in 7%
patients (Eriksson et al., 1989). Similar situation was recog-
nized during other studies (Alacra, 2009). The platelet count
was always signiﬁcantly lower (p< 0.01) in the malaria pa-
tients group as compared to the control group. All these obser-
vations substantiated the results of our current study.
In cases of P. falciparum and P. vivax infected patients,
platelet counts during infection and after treatment, and plate-
let survival during decreasing parasitaemia, concluded that 22
of 26 (85%) patients with P. falciparum malaria and 30 of 39
(72%) patients with P. vivax malaria had depressed platelet
counts below <150 · 109/L in blood (Alacra, 2009). There
was a signiﬁcant correlation between low platelet counts and
high counts of malarial plasmodia (parasitised red blood cells)
both in P. falciparum and P. vivax infections (p< 0.001).
Platelet survival, studied by malonaldehyde formation in three
patients during the period of decreasing parasitaemia, revealed
a shortened life span to 2–3 days, in comparison to 7–10 days
in normal controls. In all patients, platelet counts rose three
times more than the initial values within 5 days after clearance
of parasites. These results demonstrated again that thrombo-
cytopenia was a common feature in human malaria; and sec-
ondly, that thrombocytopenia induced by malaria was due to
shortened life span in the peripheral blood; and thirdly that
some interaction might be existing between platelets and ma-
laria plasmodia or parasitised red cells (Alacra, 2009).
Studies on the platelet counts together with coagulation
factors and cytokines in patients with malaria or meningococ-
cal infections, demonstrated a decreased level of platelet
counts as well as decreased levels of coagulation factors and
an elevated level of cytokines in both groups. The observed le-
vel of coagulation factors and cytokines in patients with P. fal-
ciparum malaria reverted to normal within 3–5 days after
initiation of therapy (Bygbjerg et al., 1997).
In earlier studies, a correlation between histamine changes,
clinical complications, reduction of C’3 and degree of throm-
bocytopenia in P. falciparum infection was pointed out (Sri-
chaikul et al., 1976). However, a reversible suppression of
platelet aggregation in malarial patients and a correlation be-
tween this suppression and thrombocytopenia was conﬁrmed
(Srichaikul et al., 1988). Similarly studies on elevated plasma
levels of P-selectin (GMP-140/CD62P) were also investigated,
which is produced by activated platelets and endothelial cells.
In patients with P. falciparum malaria, no correlation between
P-selectin levels and parasitaemia could be concluded (Facer
and Theodoridou, 1994).
It was proposed that splenic pooling and an immunologi-
cally mediated shortened platelet life span might be one of
the major causes of the thrombocytopenia which accompanies
malaria infection (Hutton et al., 2001). It is worth mentioning
that the association between malaria infection and platelets
was also observed in animal models (Hutton et al., 2001; Kak-
oma et al., 1992; Grau et al., 1988).
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tions revealed that thrombocytopenia was a common feature
seen in severe falciparum malaria. It was presumed to be due
to increased consumption of the platelets in the periphery, per-
haps in the spleen. However, bleeding due to thrombocytope-
nia is very rare in malaria (Johnston et al., 2009).
Thrombocytopenia is almost invariable in malaria and so
may be helpful as a sensitive but non-speciﬁc marker of active
infection. However, severe thrombocytopenia (<50 · 109/L) is
rare. Increased removal of platelets may follow absorption of
immune complexes, but there is no evidence for platelet-spe-
ciﬁc alloantibodies (Weatherall et al., 2002).
Bleeding and coagulation abnormalities are seen only in
limited number of patient with sever falciparum malaria. They
can be due to thrombocytopenia and/or disseminated intravas-
cular coagulation (DIC). Hypoﬁbrinogenaemia due to DIC oc-
curs only in 5% of patients. Mature parasitized red cell and
cytokines both can activate the coagulation cascade. Acceler-
ated coagulation cascade, consumption of antithrombin III,
increased concentration of FDP and increased splenic clear-
ance of platelets, contribute well to the coagulopathy and
thrombocytopenia in malaria (Johnston et al., 2009; Weather-
all et al., 2002).
Haemoglobinuria due to massive intravascular haemolysis
can occur in falciparum malaria. It is usually observed in
non- or semi-immune individuals. Formerly immune individu-
als who have lost their immunity by remaining for a prolonged
period in a non-malarious area also develop the complication
if they happen to contract malaria on their return to a malar-
ious area (www.malariasite.com, 2006).
The intravascular haemolysis can be due to non-immune
destruction of parasitised red cells in case of high parasitaemia
or parasitised red cells as well as non-parasitised red cells. The
changes in the red cell antigen structure brought about by the
parasitic invasion stimulate the production of antibodies to the
red cell. This triggers immune-mediated red cell lysis. Patients
with a deﬁciency of glucose 6-phosphate dehydrogenase en-
zyme may develop haemolysis when treated with oxidant drugs
like Primaquine. The increased release of haemoglobin in the
circulation results in haemoglobinuria and the urine appears
dark brown or black (black water fever) www.malariasite.com,
2006.
The lowering of cholesterol level in the current study was
statistically highly signiﬁcant (p< 0.001) in the patient group
as compared to the control group. The Mann–Whitney value
for cholesterol was 7651.5. There was a highly signiﬁcant
(p< 0.001) correlation between cholesterol and the parasitic
load in the patient group. A signiﬁcant inverse correlation be-
tween parasite count and serum cholesterol level was also no-
ticed. Our ﬁndings on reduction of cholesterol levels
(p< 0.001) in malaria infection added support to earlier re-
ports where hypocholesterolaemia was strongly associated with
malaria and was considered as a speciﬁc indicator (with 95%
speciﬁcity) for the diagnosis of malaria (Badiaga et al., 2002).
The mean cholesterol level was signiﬁcantly lower
(p< 0.001) in malaria patients than in their matched controls.
The results obtained during our current study are in agreement
with those reported earlier.
The low level of cholesterol observed in malaria mainly oc-
cur due to decreased HDL and possibly LDL. Actually the low
levels of the HDL is associated with reduction in the transport
of cholesterol, esteriﬁcation by lecithin cholesterol acyl trans-ferase, and/or to the liver due to the enzyme inhibition by a
parasite factor. The uptake of the host cholesterol and
phospholipids by the parasite, and adverse effects on HDL-
generating enzyme are some of the factors leading to hypoc-
holestrimia, however, the rapid fall of HDL in malaria might
be due to its extra-vasation, rather than to a decreased rate
of synthesis (Richards et al., 1998; Eriksson et al., 1989; Kitti
et al., 1992; Kain and Keystone, 1998; Mohanty et al., 1992;
Nilsson-Ehle and Nilsson-Ehle, 1990; Svenson et al., 1995;
Vernes et al., 1980; Shalmiev and Ginsburg, 1993; Hansmann
et al., 1997).
It is worth mentioning that splenomegaly is frequent in
acute or chronic forms of P. falciparum malaria, and splenec-
tomy is associated with more frequent fever and parasitaemia.
A novel role for the spleen in malaria is indicated by recent epi-
demiological and experimental data, bringing about a novel
paradigm on severe malaria pathogenesis (Buffe et al., 2009).
Earlier, the relation between malaria infection and lipid
metabolism was also studied in culture of P. falciparum
in vitro experiments and following explanation was given:
 Uninfected erythrocytes in the culture serve as a major
source for the increased lipid content of malaria-infected
cells.
 An inverse relationship was observed between the levels of
acidic phospholipids and cholesterol.
 Resistance to chloroquine and/or quinine was found to be
directly related to the level of acidic phospholipids, while
that of meﬂoquine displayed an inverse correlation. The
resistance to chloroquine was inversely related to the con-
tent of cholesterol, while the sensitivity to meﬂoquine
decreased with cholesterol concentration. Continued sur-
veillance was needed to ensure that patients continue to
receive optimal therapy (Gutman et al., 2009; Laxminara-
yan and Gelband, 2009).
5. Conclusion
It is evident from the results of our current study that there was
a highly signiﬁcant reduction in the serum cholesterol level and
the platelet count in correlation with high levels of parasitaemia
in malaria patients; however, there might be other factors that
cause lowering in serum cholesterol level and the platelet count
that may be differentiated, such as generalised haemodilution,
and pregnancy. However, in pregnancy some factors are known
to increase the cholesterol and lipids levels, and balance hypo-
cholesterolaemia caused by haemodilution alone.
Other causes of thrombocytopenia and hypocholesterola-
emia should be taken into consideration when comparing ﬁnd-
ings in malaria patients. This relative speciﬁcity, however, does
not invalidate the usefulness of these ﬁndings in cases of malar-
ia. Our ﬁndings could be utilised in monitoring the effect of
malaria treatment; but more work is needed to relate these
ﬁndings to the presence of any parasite component, a fact that
will be of value for further studies to exclude relapses and
recrudescence.
In addition, the documented low levels of cholesterol and
platelets that accompany the malaria positive cases are of sig-
niﬁcant value in supporting the clinical diagnosis of malaria in
the absence of a positive blood ﬁlm.
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